Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21255398)

  • 1. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
    Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
    Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.
    Atienza JM; Roth RB; Rosette C; Smylie KJ; Kammerer S; Rehbock J; Ekblom J; Denissenko MF
    Mol Cancer Ther; 2005 Mar; 4(3):361-8. PubMed ID: 15767545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas.
    Deb S; Xu H; Tuynman J; George J; Yan Y; Li J; Ward RL; Mortensen N; Hawkins NJ; McKay MJ; Ramsay RG; Fox SB
    Br J Cancer; 2014 Mar; 110(6):1606-13. PubMed ID: 24548858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability.
    Yun J; Song SH; Kang JY; Park J; Kim HP; Han SW; Kim TY
    Nucleic Acids Res; 2016 Jan; 44(2):558-72. PubMed ID: 26420833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
    Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
    Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
    Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
    Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation.
    Zhu S; Zhao L; Li Y; Hou P; Yao R; Tan J; Liu D; Han L; Huang B; Lu J; Zhang Y
    J Cell Biochem; 2016 Jun; 117(6):1359-69. PubMed ID: 26529363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
    Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
    Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
    Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
    Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
    Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
    Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
    Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
    Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.